- JP-listed companies
- KNC Laboratories Co., Ltd.
- Income statement
KNC Laboratories Co., Ltd. (6568) Income statement
Market cap
¥9.8B
P/E ratio
12.7x
Develops and manufactures specialized organic chemicals for pharmaceutical, electronics, and biotech companies to accelerate their product development.
| 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 4,005 | 3,812 | 4,541 | 4,768 | 6,313 | 6,291 | 6,348 | 6,029 | 7,441 | 8,628 | 9,155 | 8,179 | 9,094 |
| Revenue growth (%) | - | ||||||||||||
| Cost of revenue | - | - | - | 3,321 | 4,088 | 3,943 | 4,617 | 4,270 | 5,333 | 5,324 | 5,859 | 5,858 | 6,705 |
| Gross profit | - | - | - | 1,447 | 2,225 | 2,347 | 1,730 | 1,760 | 2,107 | 3,304 | 3,296 | 2,321 | 2,388 |
| Gross margin (%) | - | - | - | ||||||||||
| Operating margin (%) | - | - | - | ||||||||||
| Operating expenses | - | - | - | 738 | 1,003 | 1,107 | 1,156 | 1,124 | 1,013 | 1,140 | 1,214 | 1,549 | 1,364 |
| Operating income | - | - | - | 709 | 1,222 | 1,240 | 574 | 635 | 1,095 | 2,164 | 2,081 | 772 | 1,025 |
| Income before tax | 282 | 218 | 410 | 741 | 1,209 | 1,285 | 645 | 677 | 1,103 | 2,199 | 2,095 | 930 | 1,029 |
| Pretax margin (%) | 7.1 | 5.7 | 9 | 15.5 | 19.1 | 20.4 | 10.2 | 11.2 | 14.8 | 25.5 | 22.9 | 11.4 | 11.3 |
| Provision for income taxes | - | - | - | 238 | 327 | 359 | 186 | 186 | 273 | 630 | 600 | 191 | 260 |
| Effective tax rate (%) | - | - | - | ||||||||||
| Net income | 288 | 182 | 108 | 484 | 901 | 936 | 518 | 400 | 643 | 1,543 | 1,493 | 737 | 766 |
| Earnings per share | 287,976.78 | 182,019.02 | 17.93 | 80.72 | 148.35 | 121.29 | 67.02 | 51.54 | 82.78 | 200.06 | 193.5 | 95.42 | 99.02 |
| Dividend per share | - | - | - | - | - | - | 25 | 25 | 25 | 28 | 30 | 33 | 33 |